Document is current
Any future updates will be listed below
-
Authors
Reeves, Brandi N.
Masarova, Lucia
Abu-Zeinah, Ghaith
Hunter, Anthony M.
Shatzel, Joseph J.
Qin, Albert
Yoon, Chang Ho
Cai, Ling-Yu
Wei, Yu-Feng
Mesa, Ruben A.
-
Funding
Funding for this research was provided by:
The research and open access are supported by PharmaEssentia.
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 19 June 2025
First Online: 10 July 2025
Declarations
:
: Not applicable.
: Not applicable.
: Brandi Reeves: has received consulting fees from PharmaEssentia, CTI BioPharma, and Incyte. Lucia Masarova: advisory board participation with Cogent, GSK, MorphoSys, and PharmaEssentia. Ghaith Abu-Zeinah: research support provided to the institution from PharmaEssentia. Anthony M Hunter: has received honoraria/consulting fees from GSK, Cogent Biosciences, PharmaEssentia, Blueprint Medicines, CTI Biopharma (now Sobi) and Incyte; declares research funding from Incyte, Cogent Biosciences, Ascentage Pharma, Blueprint Medicines, Syntrix Biosystems, Novartis, and PharmaEssentia. Joseph Shatzel: No relevant Conflicts. Albert Qin: serves as chief medical officer of PharmaEssentia. Chang Ho Yoon: consultant for PharmaEssentia. Ling-Yu Cai: employee of Vizuro LLC which has provided data analysis for PharmaEssentia Yu-Feng Wei: co-founder and CEO of Vizuro LLC which has provided data analysis for PharmaEssentia. R Mesa: consultant (Honoraria) over past 3 years: Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology, Telios; Research Support: Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys, Sierra.
